Multistate salmonella outbreak linked to recalled frozen sprouted beans: CDC, FDA
Since last fall, 11 people have been diagnosed with salmonella, data from the Centers for Disease Control and Prevention shows, with most of the cases occurring since early April. According to the CDC, Massachusetts has seen two cases in connection with this outbreak. Connecticut, Florida, Illinois, Minnesota, New Jersey, Pennsylvania, Tennessee, Virginia, and Washington have all recorded single cases.
Patients range in age from less than a year old to 78 years old, and many of them said they had shopped at Indian grocery stores and consumed Indian cuisine. Four said they ate or likely ate sprouted beans.
Which companies have agreed to drop artificial food dyes?
The CDC said testing done by the Food and Drug Administration in May revealed samples of frozen sprouted mat, or moth, and moong beans tested positive for the same salmonella strain found in those who became ill.
'This means that people likely got sick from eating sprouted beans,' the CDC explained.
Which products have been recalled?
On Wednesday, Chetak LLC Group issued a recall for packages of Deep brand frozen Sprouted Mat (Moth) and Sprouted Moong. Both products were sold in 16-ounce pouches, the notice on the FDA website reads. Impacted packages will have one of the following lot codes printed on the back of the bag:
Sprouted Mat (Moth): 24330, 25072, 25108, 24353, 25171, 24297, 25058, 25078, 24291, 25107, 24354, 24292
Sprouted Moong: 24330, 25072, 25108, 24353, 25171, 24297, 25058, 25078, 24291, 25107, 24354, 24292
The company said that while 'no illness have been reported to date in connection with this problem to company,' the sprouted beans were recalled over potential salmonella contamination that 'was noted after routine testing by FDA.' Meanwhile, an investigation into 'the source of the problem' is ongoing.
If you have any of the recalled product, you are asked to return it for a full refund.
What is salmonella?
It's caused by the salmonella bacteria, which the CDC estimates cause 1.35 million infections, 26,500 hospitalizations, and 420 deaths in the U.S. yearly.
Salmonella infections are commonly associated with diarrhea, fever and stomach cramps, according to the CDC. Symptoms can begin between six hours and six days after you've ingested the bacteria. Most people can recover without receiving treatment within four to seven days.
Illnesses may be more severe for young children, the elderly and those with weakened immune systems. Some may require medical treatment or hospitalization, the CDC explains. Infections can only be diagnosed with a laboratory test of a person's stool, body tissue or fluids.
Other recent salmonella outbreaks have been linked to pistachio cream, eggs, and cucumber products.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
22 minutes ago
- CBS News
Third human case of West Nile virus in Illinois reported in DuPage County
A Third human case of West Nile virus in Illinois has been reported, this time in DuPage County. The DuPage County Health Department confirmed the case on Thursday. The department said the individual is a Glen Ellyn resident in their 50s, and the onset of symptoms was mid-July. The Centers for Disease Control and Prevention first confirmed in June that a person downstate, specifically in Southern Illinois, was hospitalized due to complications of the virus. The second was confirmed in Lake County on July 16. The resident was said to be in their 70s and became ill earlier in the month. Symptoms of West Nile virus While most people infected with the virus do not feel sick, about one in five will develop a fever and flu-like symptoms. Other symptoms include body aches, vomiting, diarrhea, or rash. Severe illness can occur in about one in 150 people and is most likely to occur in people over age 55 or with weakened immune systems. How to prevent it West Nile virus is spread to people from infected mosquitoes, most commonly in the summer. Eight out of 10 people infected do not develop symptoms, according to the CDC. Residents are also reminded to practice the three "R's"– reduce the number of mosquitoes and remove containers outside that hold water, repel mosquitoes by using insect repellent, and report areas where water sits for more than a week. There are no medications to treat the virus. The only way to combat the virus is to prevent mosquito bites.
Business Upturn
an hour ago
- Business Upturn
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Yahoo
2 hours ago
- Yahoo
Measles cases in US over 4.5 times higher than all of last year
Measles cases in the United States are continuing to rise after breaking a decades-long record just two weeks ago. There are now 1,319 confirmed measles cases across 39 states, according to data from the Centers for Disease Control and Prevention (CDC) updated Wednesday. This is the highest nationwide measles figure seen since 1992. National cases are more than 4.5 times higher than the entirety of last year, which had an estimated 285 cases reported. MORE: Amid growing Texas outbreak, how contagious is measles? So far, two children and one adult have died from the virus this year, the first deaths from measles in a decade. About one to three of every 1,000 children infected with measles die from respiratory and neurologic complications, according to the CDC. An overwhelming majority of this year's cases -- 92% -- are among those who were unvaccinated or whose vaccination status is unknown, CDC data shows. Measles was declared eliminated from the U.S. in 2000 due to a highly effective vaccination program, according to the CDC Childhood vaccination rates to protect against measles have been declining in recent years, CDC data shows. The rate of kindergarteners receiving state-required vaccinations dropped from 95% in the 2019-2020 school year to less than 93% in the 2023-2024 school year, according to CDC data. A 95% threshold is the ideal level to protect for herd immunity, public health experts note. This leaves about 280,000 U.S. kindergarteners, or 7.3%, without protection from the virus. MORE: Amid growing Texas outbreak, how contagious is measles? A measles vaccine became available in 1963. Prior to that, nearly all children got measles by the time they were 15 years old. It led to an estimated 500 deaths and 48,000 hospitalizations each year before the shot was widely available, according to the CDC. Children in the U.S. are recommended to receive the two-dose measles, mumps, and rubella (MMR) vaccine with the first dose at 12 to 15 months of age and the second between 4 and 6 years old. One dose is 93% effective, and two doses are 97% effective, the CDC says. A booster shot is not typically recommended for adults who already have immunity from the virus through vaccination or prior infection.
